| Literature DB >> 32647120 |
Anne Straumfors1, Nur Duale2, Oda A H Foss3, Steen Mollerup3.
Abstract
Dust from grain and feed production may cause adverse health effects in exposed workers. In this study we explored circulating miRNAs as potential biomarkers of occupational grain dust exposure. Twenty-two serum miRNAs were analyzed in 44 grain dust exposed workers and 22 controls. Exposed workers had significantly upregulated miR-18a-5p, miR-124-3p and miR-574-3p, and downregulated miR-19b-3p and miR-146a-5p, compared to controls. Putative target genes for the differentially expressed miRNAs were involved in a range of Kyoto Encyclopedia of Genes and Genomes signaling pathways, and 'Pathways in cancer' and 'Wnt signaling pathway' were common for all the five miRNAs. MiRNA-diseases association analysis showed a link between the five identified miRNAs and several lung diseases terms. A positive correlation between miR-124-3p, miR-18a-5p, and miR-574-3p and IL-6 protein level was shown, while miR-19b-3p was inversely correlated with CC-16 and sCD40L protein levels. Receiver-operating characteristic analysis of the five miRNA showed that three miRNAs (miR-574-3p, miR-124-3p and miR-18a-5p) could distinguish the grain dust exposed group from the control group, with miR-574-3p as the strongest predictor of grain dust exposure. In conclusion, this study identified five signature miRNAs as potential novel biomarkers of grain dust exposure that may have potential as early disease markers.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32647120 PMCID: PMC7347934 DOI: 10.1038/s41598-020-68296-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the study population of grain and animal feed industry workers in Norway, including 44 grain dust exposed workers and 22 assumed unexposed administrative workers as controls.
| Exposed workers ( | Controls ( | |
|---|---|---|
| Age (year)a | 45 (16–61) | 49 (31–60) |
| Height (cm)a | 180 (162–195) | 178 (160–191) |
| Weight (kg)a | 89 (63–121) | 90 (58–99) |
| Body mass index (kg/m2)a | 27 (22–36) | 27 (23–32) |
| Cold (in %) | 19 | 27 |
| Farm childhood (in %) | 36 | 46 |
| Living at a farm (in %) | 23 | 32 |
| RPE use (in %) | 21 | 0 |
| FVC % of predicted at baselinea | 94 (66–133) | 99 (82–122) |
| FEV1% of predicted at baselinea | 91 (68–127) | 94 (71–120) |
RPE respiratory protective equipment, FVC forced vital capacity, FEV forced expired volume in the first second.
aMedian (min–max).
Full-shift bioaerosol exposure of grain and animal feed industry workers in Norway.
| Exposure parameter | AM | GM | GSD | Above OEL (%) | |
|---|---|---|---|---|---|
| Grain dust (mg/m3) | 44 | 1.6 | 0.9 | 3.00 | 7 |
| Endotoxin (EU/m3) | 43 | 1,252 | 439 | 5.15 | 84 |
| β-1 → 3-glucan (µg/m3) | 44 | 14.7 | 6.4 | 4.49 | No OEL |
| Bacteria (counts/m3) | 44 | 52 × 104 | 20 × 104 | 5.53 | 14 |
| Fungal spores counts/m3) | 44 | 7.8 × 104 | 3.5 × 104 | 3.30 | 18 |
AM arithmetic mean, GM geometric mean of log10 transformed values, GSD geometric standard deviation, OEL occupational exposure limit. Norwegian OELs: grain dust (organic dust) = 5 mg/m3; endotoxins = 90 EU/m3 (health-based recommended); bacteria = 106 counts/m3 (suggested based on lowest observed effect levels); fungal spores = 105 counts/m3 (suggested based on lowest observed effect levels).
Serum protein concentrations of dust exposed workers and unexposed controls in the Norwegian grain and animal feed industry.
| Exposed workers ( | Controls ( | Group differences | ||||
|---|---|---|---|---|---|---|
| GM (GSD) | GMadj (GSE) | GM (GSD) | GMadj (GSE) | |||
| – | – | |||||
| SP-D (ng/mL) | 99.7 (1.7) | 105 (1.1) | 101 (1.9) | 112 (1.1) | 0.9 | 0.6 |
| SP-A (µg/mL) | 24.3 (11.7) | - | 38 (5.8) | – | 0.4 | – |
| TNF-α (pg/mL) | 1.1 (1.3) | 1.1 (1.1) | 1.1 (1.4) | 1.1 (1.1) | 0.9 | 0.9 |
| Fibrinogen (mg/mL) | 3.3 (1.4) | – | 3.8 (1.3) | – | 0.1 | |
| CRP (mg/L) | 1.5 (2.9) | 1.4 (1.2) | 1.3 (2.7) | 1.3 (1.2) | 0.7 | 0.8 |
| sCD40L (ng/mL) | 2.0 (2.5) | 1.9 (1.2) | 1.5 (2.7) | 1.6 (1.2) | 0.3 | 0.4 |
| sP-selectin (ng/mL) | 52.7 (1.6) | – | 51 (1.7) | – | 0.8 | – |
GM geometric mean, GSD geometric standard deviation, GM geometric mean adjusted for confounders, GSE standard error of GMadj; adjustments. SP-D % body fat and farm childhood, IL-6% body fat, TNF-α age and % body fat, CRP age and % body fat, sCD40L % body fat.
Differences in the GM between exposed workers and controls were tested by independent sample t tests. Significant different concentrations, as judged by a p value ≤ 0.05, are highlighted in bold.
Figure 1Heat map of miRNA expression profile in exposed workers and controls. Unsupervised hierarchical clustering analysis of the relative expression level of 22 miRNAs (measured by qPCR), and the clustering analysis is based on similarities in miRNA expression pattern. Red pixels represent up-regulated miRNAs whereas green pixels represent down-regulated miRNAs. Samples are horizontally labelled based on the exposure group they belong to (blue: exposed group and purple: control group). Vertically, blue labelled miRNAs (n = 5) indicate significantly differentially expressed miRNAs. Data are presented as log2-transformed normalized relative expression values.
Figure 2Fold change (SE) of miRNAs in exposed workers relative to controls. Only miRNA significantly different between exposed and controls are shown.
List of KEGG signaling pathways involving the five differentially expressed miRNAs predicted by their putative target genes.
| Pathway name | # predicted target genes | # genes | FDR | |
|---|---|---|---|---|
| hsa-miR-574-3p (n = 12) | ||||
| Axon guidance | 97 | 129 | 1.85E−08 | 3.59E−06 |
| Neurotrophin signaling pathway | 93 | 129 | 1.00E−06 | 1.90E−04 |
| Endocytosis | 128 | 187 | 1.18E−06 | 2.24E−04 |
| MAPK signaling pathway | 178 | 272 | 1.27E−06 | 2.41E−04 |
| 207 | 330 | 1.41E−05 | 2.60E−03 | |
| Long term potentiation | 54 | 71 | 1.49E−05 | 2.75E−03 |
| ErbB signaling pathway | 65 | 89 | 2.11E−05 | 3.85E−03 |
| 102 | 152 | 4.98E−05 | 8.96E−03 | |
| T cell receptor signaling pathwaya | 76 | 110 | 1.03E−04 | 1.84E−02 |
| Apoptosis | 62 | 87 | 1.09E−04 | 1.92E−02 |
| Chemokine signaling pathway | 122 | 189 | 1.37E−04 | 2.43E−02 |
| Non small cell lung cancer | 41 | 54 | 1.71E−04 | 3.01E−02 |
| hsa-miR-124-3p (n = 13) | ||||
| 295 | 330 | 7.16E−08 | 1.39E−05 | |
| Adherens junction | 73 | 76 | 8.44E−08 | 1.63E−05 |
| Axon guidance | 121 | 129 | 1.20E−06 | 2.32E−04 |
| Endocytosis | 170 | 187 | 3.32E−06 | 6.34E−04 |
| Fc gamma R mediated phagocytosisa | 92 | 97 | 5.87E−06 | 1.12E−03 |
| Small cell lung cancer | 80 | 84 | 1.52E−05 | 2.84E−03 |
| Gap junction | 85 | 90 | 2.29E−05 | 4.25E−03 |
| Ubiquitin mediated proteolysis | 122 | 134 | 6.88E−05 | 1.21E−02 |
| Regulation of actin cytoskeletona | 187 | 212 | 1.22E−04 | 2.10E−02 |
| Neurotrophin signaling pathway | 117 | 129 | 1.49E−04 | 2.57E−02 |
| Long term potentiation | 67 | 71 | 1.94E−04 | 3.32E−02 |
| 136 | 152 | 2.24E−04 | 3.81E−02 | |
| Chemokine signaling pathway | 167 | 189 | 2.25E−04 | 3.83E−02 |
| Insulin signaling pathway | 125 | 139 | 2.34E−04 | 3.98E−02 |
| hsa-miR-18a-5p (n = 4) | ||||
| 313 | 330 | 1.81E−05 | 3.51E−03 | |
| Chemokine signaling pathway | 182 | 189 | 6.00E−05 | 1.16E−02 |
| 147 | 152 | 1.46E−04 | 2.78E−02 | |
| Ubiquitin mediated proteolysis | 130 | 134 | 2.10E−04 | 3.99E−02 |
| hsa-miR-146a-5p (n = 11) | ||||
| 293 | 330 | 1.81E−13 | 3.51E−11 | |
| Adherens junction | 73 | 76 | 8.44E−08 | 1.63E−05 |
| 135 | 152 | 6.04E−07 | 1.16E−04 | |
| Small cell lung cancer | 78 | 84 | 2.28E−06 | 4.31E−04 |
| MAPK signaling pathway | 228 | 272 | 4.98E−06 | 9.37E−04 |
| Apoptosis | 79 | 87 | 1.97E−05 | 3.64E−03 |
| ErbB signaling pathway | 80 | 89 | 4.46E−05 | 8.03E−03 |
| Gap junction | 80 | 90 | 1.16E−04 | 2.03E−02 |
| Ubiquitin mediated proteolysis | 115 | 134 | 1.49E−04 | 2.59E−02 |
| Non-small cell lung cancer | 50 | 54 | 2.07E−04 | 3.57E−02 |
| TGF beta signaling pathwaya | 76 | 86 | 2.70E−04 | 4.62E−02 |
| hsa-miR-19b-3p (n = 7) | ||||
| 287 | 330 | 4.34E−09 | 8.43E−07 | |
| 134 | 152 | 1.24E−05 | 2.36E−03 | |
| Endocytosis | 162 | 187 | 1.70E−05 | 3.23E−03 |
| Ubiquitin mediated proteolysis | 118 | 134 | 4.60E−05 | 8.65E−03 |
| Insulin signaling pathway | 121 | 139 | 1.22E−04 | 2.23E−02 |
| Small cell lung cancer | 76 | 84 | 1.35E−04 | 2.45E−02 |
| Adherens junction | 69 | 76 | 2.12E−04 | 3.79E−02 |
All five significantly differentially expressed miRNA target genes are enriched in pathways highlighted in italics.
aPathway enriched only in one miRNA; KEGG (Kyoto Encyclopedia of Genes and Genomes). The KEGG enrichment analyses is based on hypergeometric statistical tests, including Benjamini and Hochberg (FDR < 0.05) multiple test adjustment.
Associations between diseases and the five differentially expressed miRNAs extracted from the MNDR database.
| Disease name | miRNA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| hsa-miR-146a-5p | hsa-miR-19b-3p | hsa-miR-574-3p | hsa-miR-124-3p | hsa-miR-18a-5p | ||||||
| CS | Class | CS | Class | CS | Class | CS | Class | CS | Class | |
| Lung cancer | 0.4752 | W | 0.8939 | S | 0.8939 | S | 0.8939 | S | 0.8939 | S |
| Non-small cell lung carcinoma | 0.4752 | W | 0.7606 | S | 0.7311 | S | 0.8808 | S | 0.7606 | S |
| COPD | 0.8939 | S | 0.1097 | P | 0.1097 | P | ||||
| Asthma | 0.8589 | S | 0.1097 | P | 0.1097 | P | 0.1097 | P | ||
| Inflammation | 0.7311 | S | 0.1097 | P | 0.1097 | P | 0.1097 | P | ||
| Lacunar stroke | 0.7311 | S | 0.4752 | W | 0.4752 | W | 0.7311 | S | ||
| Carotid stenosis | 0.8808 | S | ||||||||
| Coronary artery disease | 0.1097 | P | 0.9443 | S | 0.1097 | P | 0.7606 | S | ||
| Atherosclerosis | 0.9526 | S | 0.5725 | W | 0.1097 | P | 0.1097 | P | ||
| Pulmonary hypertension | 0.9751 | S | ||||||||
| Intermediate coronary syndrome | 0.1097 | P | 0.8939 | S | 0.1097 | P | 0.1097 | P | ||
| Sepsis | 0.7311 | S | 0.4752 | W | 0.1097 | P | ||||
| Adenoviridae infections | 0.7311 | S | ||||||||
| Nasopharynx carcinoma | 0.7606 | S | ||||||||
Confidence score (CS) for miRNA-disease association range from 0.110 to 0.975. Confidence score ranges between 0 and 1; and only well-supported miRNA–disease associations obtain a value close to 1. Class denotes the evidence type for each miRNA-disease association with S representing strong experimental evidence, W representing weak experimental evidence, and P representing prediction evidence; MNDR (Mammalian NcRNA-Disease Repository).
Pearson correlations between serum miRNA and serum proteins. Log-transformed unadjusted values (n = 66).
| hsa-miR-146a-5p | hsa-miR-124-3p | hsa-miR-18a-5p | hsa-miR 19-3p | hsa-miR-574-3p | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| rp | rp | rp | rp | rp | ||||||
| 0.16 | 0.19 | − 0.04 | 0.76 | − 0.05 | 0.68 | − | 0.05 | 0.71 | ||
| SP-D | 0.06 | 0.62 | 0.14 | 0.28 | 0.16 | 0.21 | − 0.28 | 0.82 | 0.16 | 0.21 |
| SP-A | 0.06 | 0.62 | − 0.11 | 0.39 | − 0.15 | 0.23 | − 0.19 | 0.12 | − 0.06 | 0.66 |
| − 0.22 | 0.07 | − 0.12 | 0.36 | |||||||
| TNF-α | − 0.08 | 0.52 | 0.19 | 0.13 | 0.08 | 0.51 | 0.1 | 0.42 | 0.19 | 0.13 |
| Fibrinogen | 0.01 | 0.93 | − 0.008 | 0.95 | 0.004 | 0.98 | 0.18 | 0.14 | − 0.08 | 0.53 |
| CRP | − 0.06 | 0.63 | 0.1 | 0.41 | 0.09 | 0.47 | − 0.12 | 0.35 | 0.16 | 0.21 |
| sp-selectin | − 0.07 | 0.6 | − 0.11 | 0.38 | − 0.06 | 0.62 | − 0.0 | 0.73 | 0.07 | 0.56 |
| 0.13 | 0.28 | − 0.17 | 0.18 | − 0.15 | 0.23 | − | − 0.14 | 0.26 | ||
Bold values represent correlations significant at a p value ≤ 0.05.
Figure 3Receiver operating characteristic (ROC) curves with corresponding area under curve (AUC) statistics for circulating serum miRNAs to discriminate between grain dust exposed workers and controls.
Figure 4Flow chart of selection of study population and miRNA analyses.